Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14381759 | 0.93 | PRSS12 (0.64) | PRSS12LMNASMYD3CHEK2SMN1; SMN2 | |
| SCHEMBL14381762 | 0.93 | PRSS12 (0.64) | PRSS12LMNASMYD3CHEK2SMN1; SMN2 | |
| SCHEMBL14381787 | 0.93 | PRSS12 (0.64) | PRSS12LMNASMYD3CHEK2SMN1; SMN2 | |
| SCHEMBL14381814 | 0.93 | PRSS12 (0.64) | PRSS12LMNASMYD3CHEK2SMN1; SMN2 | |
| SCHEMBL14381760 | 0.92 | PRSS12 (0.62) | PRSS12LMNASMYD3CHEK2SMN1; SMN2 | |
| SCHEMBL14381772 | 0.90 | PRSS12 (0.60) | PRSS12SMYD3CHEK2SMN1; SMN2RAB9A | |
| SCHEMBL14381817 | 0.87 | PRSS12 (0.58) | PRSS12LMNASMYD3CHEK2SMN1; SMN2 | |
| SCHEMBL14381830 | 0.87 | PRSS12 (0.58) | PRSS12LMNASMYD3CHEK2SMN1; SMN2 | |
| SCHEMBL28752333 | 0.87 | SMN1; SMN2 (0.57) | PRSS12LMNASMYD3CHEK2SMN1; SMN2 | |
| SCHEMBL14381836 | 0.87 | PRSS12 (0.58) | PRSS12LMNASMYD3CHEK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282518-B2 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | SIRCAR JAGADISH C | 2007-08-30 | — | — | US | disclosed |
| EP-1368028-B1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | SIRCAR JAGADISH C (US) | 2004-10-28 | — | — | US | disclosed |
| US-6759425-B2 | USEFUL IN THE TREATMENT OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IGE IS PATHOGENIC; ALSO ARE USEFUL AS ANTICANCER AGENTS. | AVANIR PHARMACEUTICALS | 2004-07-06 | — | — | US | disclosed |
| EP-1368028-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002072090-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | MKI67, CMA1, CCNI | PRSS12 3287/4885LMNA 4667/4885SMYD3 1381/4885 |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | FCER2, CMA1, FCGR1A | PRSS12 3362/4885LMNA 4477/4885SMYD3 2973/4885 |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | MKI67, CMA1, CCNI | PRSS12 3287/4885LMNA 4667/4885SMYD3 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.